EDNRB as a Radioligand Therapy Target
EDNRB, endothelin receptor type B, is a cell-surface protein (GPCR). In Human Protein Atlas immunohistochemistry, EDNRB staining is highest in breast cancer (100% of samples positive), ovarian cancer (83% of samples positive) and pancreatic cancer (60% of samples positive). Evidence on whether EDNRB internalizes is mixed. Clinical status: Clinical-stage (up to phase 3, any modality).
Is EDNRB a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in breast cancer, 100% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: Clinical-stage (up to phase 3, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
EDNRB expression in cancer
Protein expression of EDNRB across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Breast Cancer | 0.69 | High | 100% |
| Ovarian Cancer | 0.50 | Medium | 83% |
| Pancreatic Cancer | 0.27 | Medium | 60% |
| Gastric Cancer | 0.22 | Medium | 56% |
| Cervical Cancer | 0.19 | Low | 33% |
| Kidney Cancer | 0.17 | Low | 33% |
| Colorectal Cancer | 0.14 | Low | 33% |
| Endometrial Cancer | 0.14 | Low | 33% |
| Bladder Cancer | 0.14 | Low | 25% |
| Liver Cancer | 0.14 | Low | 25% |
| Lung Cancer | 0.11 | Low | 22% |
| Thyroid Cancer | 0.08 | Low | 25% |
| Testicular Cancer | 0.04 | Low | 11% |
| Melanoma | 0.03 | Low | 10% |
Not detected by IHC in: skin cancer, head and neck cancer, lymphoma, neuroendocrine tumors, prostate cancer, glioma.
Is EDNRB internalized?
Uncertain. Insufficient literature found.
EDNRB clinical trials
Clinical-stage (up to phase 3, any modality). Nuclens hasn't indexed trials for EDNRB yet. Search ClinicalTrials.gov for EDNRB trials.
EDNRB normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See EDNRB in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
EDNRB gene essentiality (DepMap)
CRISPR knockout effect across 1252 cancer cell lines: 0.04 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related breast cancer radioligand targets
HER3 (ERBB3) · c-MET (MET) · FAP · HER2 (ERBB2) · STEAP2 · EGFR · B7-H3 (CD276) · SSTR2
See all radioligand therapy targets in breast cancer.
See how EDNRB ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.